Enzymebiosystems (ENZB) 0.4580 $ENZB Penny Stocks

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enzymebiosystems (ENZB) 0.4580 $ENZB

Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS MCB).

EnzymeBioSystems: A Promotion Best Left Untouched
Hunter Straus - at Seeking Alpha - Mon Mar 16, 11:09PM CDT


EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets" that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace.

Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 5.77 (-0.40), CTRV: 3.65 (+0.22), IDT: 17.33 (+0.06), ESCRP: 2.63 (-0.22), NNBR: 28.17 (+0.23)

EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.

Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.

Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.

EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).

EnzymeBioSystems Announces Progress with an Enzyme Compound
PR Newswire - Tue Sep 23, 1:14PM CDT
EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces they have moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 20

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 314

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 23

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 13

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 12

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 287

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

AAVantgarde's Professor Auricchio Receives Prestigious Role

Updated Category News Views 177

AAVantgarde's Professor Auricchio Achieves New Milestone MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to...

Continue Reading
How Bitcoin's Drop Affects Strategy Inc (NASDAQ: MSTR) Investors

Updated Category News Views 137

Understanding the Current Market Landscape As recent market trends demonstrate, Strategy Inc (NASDAQ: MSTR) is seeing significant activity. On one hand, the company is evidently reliant on the performance of Bitcoin. With such dependence, the fluctuations in the value of Bitcoin are crucial to the health of MSTR. This situation poses both risks and opportunities for...

Continue Reading
Significant Attorney Departures to Strengthen Association Law Firm

Updated Category News Views 99

Major Attorney Moves to Association Law Group (ALG) In a noteworthy shift within Florida's community association law landscape, several prominent attorneys have transitioned from Becker & Poliakoff to join the ranks of Association Law Group (ALG). Among them, Michael C. Gongora, Lilliana Farinas-Sabogal, and Adam Cervera are recognized for their extensive experience in...

Continue Reading
EQB's Commitment to Sustainability in Financial Services

Updated Category News Views 175

EQB Focuses on Sustainability in Its Latest Report EQB Inc. (TSX: EQB) has recently published a detailed Responsibility Report, highlighting significant strides towards its sustainability commitments. This annual report encapsulates the company's dedication to fostering an environment of innovation within the Canadian banking sector, with a particular focus on enriching...

Continue Reading
BofA's Downgrade of Sandvik: Navigating Market Pressures Ahead

Updated Category News Views 103

BofA Securities dropped a bomb on Sandvik AB back then by downgrading it from Neutral to Underperform. This move sent shockwaves through the trading floor, mainly because they saw some serious trouble brewing in Sandvik’s Machining and Manufacturing Solutions (SMMS) division. Traders were quick to pick up on the whispers about short cycle pressures that could really...

Continue Reading